Akeso and TransThera Sciences Launch Promising Phase II Study for Advanced Liver Cancer

Akeso, Inc. ((HK:9926)), TransThera Sciences (Nanjing). Inc. ((HK:2617)) announced an update on their ongoing clinical study.

Study Overview: Akeso, Inc. and TransThera Sciences (Nanjing), Inc. are conducting an open-label, multicenter Phase II clinical study titled An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet in Patients With Advanced Hepatocellular Carcinoma. The study aims to evaluate the efficacy and safety of combining AK104/AK112 with TT-00420 in treating advanced hepatocellular carcinoma (HCC), a significant cause of cancer-related deaths worldwide.

Intervention/Treatment: The study tests the combination of two drugs, AK104 and AK112, both administered intravenously, with TT-00420 (tinengotinib), taken orally. These drugs are intended to treat advanced HCC by potentially enhancing anti-tumor responses.

Study Design: This interventional study is non-randomized with a parallel assignment model. It is open-label, meaning no masking is involved, and focuses primarily on treatment. Participants are divided into cohorts for safety lead-in and expansion phases to assess the drug combination’s effectiveness.

Study Timeline: The study was first submitted on June 26, 2025, and is not yet recruiting. The primary completion and estimated study completion dates have not been disclosed, indicating the study is in its early stages. The last update was also on June 26, 2025.

Market Implications: The initiation of this study could positively influence the stock performance of Akeso and TransThera Sciences by showcasing their commitment to innovative cancer treatments. Successful outcomes may enhance investor confidence and position these companies favorably against competitors in the oncology sector.

The study is ongoing, with further details available on the ClinicalTrials portal.